Ara
Toplam kayıt 4, listelenen: 1-4
Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases
(Elsevier Inc., 2023)
Background: Neurodegenerative diseases (NDDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), are associated with metabolic abnormalities. Integrative analysis of human clinical data and animal studies ...
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: A randomised, double-blinded, placebo-controlled phase-II trial
(BioMed Central Ltd, 2023)
Background: Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed ...
Brain temperature in healthy and diseased conditions: A review on the special implications of MRS for monitoring brain temperature
(Elsevier Masson s.r.l., 2023)
Brain temperature determines not only an individual's cognitive functionality but also the prognosis and mortality rates of many brain diseases. More specifically, brain temperature not only changes in response to different ...
Infection with COVID-19 is no longer a public emergency: But what about degenerative dementia?
(John Wiley and Sons Inc, 2023)
Although no longer considered a public health threat, post-COVID cognitive syndrome continues to impact on a considerable proportion of individuals who were infected with COVID-19. Recent studies have also suggested that ...